1,3-Thiazole-4-Carboxylate

Reduction of methyl 1,3-thiazole-4-carboxylate to the corresponding aldehyde intermediate for the HIV protease inhibitor ritonavir is performed exclusively with diisobutylaluminium hydride (DIBAL‑H) in anhydrous toluene at −70 °C. A single turbidimetric probe in the cryogenic reactor jacket triggers the DIBAL‑H addition at a rate not exceeding 1.2 L·min⁻¹ in a 2 000 L glass-lined vessel. The stoichiometry is fixed at 1.05 equivalents of hydride against the ester because overdosing generates the primary alcohol impurity — (4-(hydroxymethyl)thiazol-2-yl)isopropane — which co-elutes with the target aldehyde on a Chiralpak AD‑H column (hexane‑isopropanol 95:5). After 90 min of ageing at −70 °C, the mixture is reverse-quenched into ice-cold 2 N HCl containing 5 % ammonium chloride; the quench step is the largest heat-release event in the campaign, mandating a Hastelloy C‑276 plate heat exchanger to keep the aqueous phase below 10 °C. Toluene extraction, brine washing, and fractional distillation at 8–12 mbar (head temperature 82–86 °C) deliver the aldehyde with 99.2–99.7 % HPLC purity and an enantiomeric excess >99 %. Residual aluminium is controlled to <25 ppm by ICP‑MS as per ICH Q3D; any batch exceeding this limit is re-slurried with 0.5 % EDTA tetrasodium solution. The aldehyde is stored under argon at −20 °C in UN‑rated intermediate bulk containers lined with PTFE. Full traceability to the ester starting lot is maintained in the Site Master File per EU GMP Part II. The terminal product, ritonavir polymorph Form I, requires an aldehyde of this quality for the final reductive amination step that constructs the hydroxyethylene isostere backbone without racemisation at the adjacent chiral centre.

Why Does the Methoxyimino Moiety Require Sub-Zero Quenching in Cephalosporin Side‑Chain Synthesis?

2‑Amino‑1,3‑thiazole‑4‑carboxylate methyl ester serves as the core heterocycle in the two-step assembly of (Z)‑2‑(2‑aminothiazol‑4‑yl)‑2‑methoxyiminoacetic acid — the side‑chain acid that acylates the 7‑amino group of third‑generation cephalosporins such as ceftriaxone and cefotaxime. The first step is the condensation of the 2‑amino ester hydrochloride with methoxyamine hydrochloride in water‑methanol (60:40 v/v) at pH 4.0–4.5, maintained by automated dosing of 30 % sodium hydroxide. The target methyl (Z)‑2‑(2‑aminothiazol‑4‑yl)‑2‑methoxyiminoacetate precipitates as the pure geometric isomer only when the reaction is quenched by cooling to −5 °C and seeding with authentic Z-crystals; slow cooling (0.5 °C·min⁻¹) between 25 °C and 0 °C produces 3–7 % of the unwanted E‑isomer, which cannot be purged by downstream recrystallisation and leads to an inactive 7‑amido‑cephalosporin. The wet cake is dried in a conical vacuum dryer at 40 °C and 30 mbar, with a loss on drying target of <0.5 %. Residual methanol and methylene chloride are monitored according to USP〈467〉Procedure A, with acceptance limits of <3 000 ppm and <600 ppm respectively.

Saponification of the methyl ester to the free (Z)‑oxime acid is conducted with 1.05 equivalents of aqueous lithium hydroxide in THF‑water (4:1) at 10–15 °C, followed by pH adjustment to 2.5 with 6 N sulphuric acid. The acid is extracted into isopropyl acetate, concentrated under vacuum, and crystallised from ethyl acetate‑cyclohexane to yield a product with an assay >99.0 % by anhydrous titration. During the active-ester formation step — typically the dicyclohexylcarbodiimide‑mediated coupling to 2‑mercaptobenzothiazole or the formation of the benzothiazolyl thioester — moisture ingress above 0.05 % Karl Fischer in the reaction matrix triggers premature hydrolysis of the activated intermediate. For this reason, the coupling vessel is inerted with dry nitrogen (dew point <−50 °C) and equipped with in-line NIR monitoring of the carbonyl conversion. The final side‑chain active ester is shipped under argon in double polyethylene liners packed in UN‑approved fibre drums. This intermediate is listed in the Drug Master File of ceftriaxone sodium sterile API, which must comply with Ph.Eur. monograph 01/2024:0341 and ICH Q6B for product-related substances; each batch is tested for the E‑isomer by HPLC using a C18 column with a mobile phase of acetonitrile‑phosphate buffer pH 3.0 (15:85) at 220 nm.

Production batches of the ATP‑competitive Syk inhibitor fostamatinib highlight a recurring problem in amide bond formation when the free 1,3‑thiazole‑4‑carboxylic acid is employed directly. The molecule’s central pharmacophore — 2‑aminothiazole‑4‑carboxamide — is built from 2‑amino‑1,3‑thiazole‑4‑carboxylic acid and 3‑[(6‑methylpyridin‑3‑yl)oxy]‑6‑oxo‑1,6‑dihydropyridazine‑4‑amine via a mixed‑anhydride strategy. The acid is first converted to the mixed anhydride with isobutyl chloroformate (1.03 equivalents) and N‑methylmorpholine (1.10 equivalents) in anhydrous tetrahydrofuran at −15 °C; the activation yield drops from 93 % to <70 % when the reactor headspace relative humidity exceeds 15 % because the anhydride hydrolyses within 20 min. The anhydride solution is filtered through a 0.45 μm PTFE cartridge to remove N‑methylmorpholinium chloride, then added dropwise to a slurry of the aniline component in THF‑water (9:1) maintained at −5 °C. Coupling completion is verified by HPLC at 254 nm with a target conversion >98 %; unreacted aniline above 0.15 % must be scavenged with polymer‑bound isocyanate resin (NCO loading 1.5 mmol·g⁻¹) to meet the intermediate specification for genotoxic impurity control under ICH M7 Category 3.

The crude fostamatinib free base is crystallised from acetone‑water (70:30) containing 0.5 % triethylamine. A controlled cooling ramp from 55 °C to 2 °C over 6 h with intermittent seeding yields a mean particle size D₅₀ of 18–25 μm, essential for the subsequent disodium hexahydrate salt formation because oversized crystals slow the dissolution rate and compromise polymorphic purity. Residual palladium — introduced during an upstream Suzuki coupling of the pyridazine fragment — is controlled to <3 ppm by treatment with trimercaptotriazine silica scavenger at 60 °C for 2 h. Final isolation of the disodium salt hexahydrate is performed in an isolator meeting ISO 14644‑1 Class 7 conditions, with continuous particle monitoring per EU GMP Annex 1. The dried API batch is released only when polymorphic Form B is confirmed by XRPD (characteristic peaks at 7.8, 12.2, 16.5 °2θ) and the residual acetonitrile content is <410 ppm by headspace GC‑FID.

Solvothermal Coordination to Zn₄O Nodes Yields a Pore-Opening Hysteresis in Thiazole‑4‑Carboxylate MOFs

Solvothermal assembly of a zinc‑based metal‑organic framework utilising the 1,3‑thiazole‑4‑carboxylate ligand follows a modulated synthesis protocol adapted from MFU‑4 topology. Zinc nitrate hexahydrate and 1,3‑thiazole‑4‑carboxylic acid are dissolved in N,N‑dimethylformamide at a metal‑to‑ligand molar ratio of 1.5:1, together with 25 equivalents of formic acid as the crystallisation modulator. The solution is sealed in a PTFE‑lined autoclave and heated at 135 °C for 48 h under autogenous pressure. After cooling to ambient temperature at 0.5 °C·min⁻¹, the octahedral crystals are washed with DMF and methanol and activated at 120 °C under dynamic vacuum (<10⁻⁶ bar) for 12 h. Nitrogen physisorption at 77 K according to DIN 66134 gives a type‑IV isotherm with a pronounced hysteresis loop between p/p₀ 0.42 and 0.65, corresponding to a gate‑opening pressure triggered by the thiazole ring flipping at the pore window. The Brunauer‑Emmett‑Teller surface area is 1 120 m²·g⁻¹, and the pore size distribution calculated via density functional theory centres at 9.4 Å. This flexible framework selectively adsorbs CO₂ over CH₄ with an ideal adsorbed solution theory selectivity of 14.5 at 1 bar and 298 K, a performance benchmark that makes the material a candidate for mixed‑matrix membrane fillers in natural gas sweetening. Scale‑up to a 50 L reactor is challenged by the exothermicity of the formic acid‑mediated modulation; a jacket temperature ramp of 1 °C·min⁻¹ is required between 60 °C and 100 °C to prevent amorphous precipitation. The thiazole‑4‑carboxylate ligand itself must contain <0.3 % sulphur‑bearing impurities — measured by combustion ion chromatography — to avoid pore blockage during framework assembly.

When Palladium(II) Acetate Requires a Thiazole-Derived Biarylphosphine for Challenging C–N Bond Formation

Coupling of 2‑iodo‑1,3‑thiazole‑4‑carboxylate ester with dibenzylamine in the presence of Pd(OAc)₂ and a biarylphosphine ligand demonstrates a unique substrate activation pathway. The pre‑catalyst system is formed in situ by combining 0.5 mol% Pd(OAc)₂ and 1.0 mol% dicyclohexyl(2′,4′,6′‑triisopropyl‑[1,1′‑biphenyl]‑2‑yl)phosphine (XPhos) in tetrahydrofuran at 25 °C for 15 min under nitrogen. The electron‑withdrawing 4‑carboxylate group significantly retards oxidative addition of the 2‑iodide; differential scanning calorimetry of the reaction mixture reveals an onset temperature of 42 °C, below which no conversion is detectable. The coupling is therefore run at 50 °C with 1.2 equivalents of potassium tert‑butoxide as the base, reaching 96 % conversion within 3 h as monitored by GC‑MS. When 2‑bromo or 2‑chloro analogues are attempted, the yield drops to <15 % under identical conditions, establishing that the C–I activation barrier is the rate‑limiting step. The resulting 2‑aminothiazole‑4‑carboxylate esters are subsequently hydrolysed and elaborated into N‑heterocyclic carbene precursors or into chelating P,N‑ligands for further Suzuki–Miyaura applications. Residual palladium is removed by filtration through activated carbon (Darco KB‑B, 5 wt% relative to product) and confirmed to be <2 ppm by ICP‑OES, in line with the European Pharmacopoeia recommendation for metal catalyst residues when the ligand is embedded in a pharmaceutical manufacturing chain.